The author is primarily concerned with______.

A．has been reviewed by the FDA and specifically rejected
B．has medical value but has not yet been approved by FDA for inclusion as a labeled use
C．is authorized by the label as approved by the FDA on the basis of scientific studies
D．is made in experiments designed to determine whether a drug is medically beneficial

A．the increased cost to the patient of buying an FDA-approved drug
B．the medical benefits which can accrue to the patient through unlabeled use
C．the time lag between initial discovery of a medical use and FDA approval of that use .
D．the possibility that a medically beneficial use may never be clinically documented